Non-driver mutations, such as those in ASXL1, EZH2, TET2, SRSF2, and IDH1/IDH2, have been found to exacerbate disease severity, accelerate progression, and increase the risk of transformation to acute myeloid leukemia (AML). Here, TET2 is linked to acute myeloid leukemia.